» Articles » PMID: 22184239

Checkpoint Kinase 1 (Chk1)-short is a Splice Variant and Endogenous Inhibitor of Chk1 That Regulates Cell Cycle and DNA Damage Checkpoints

Overview
Specialty Science
Date 2011 Dec 21
PMID 22184239
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Checkpoint kinase 1 (Chk1) is a key regulator of checkpoint signaling in both the unperturbed cell cycle and DNA damage response. Under these conditions, Chk1 becomes active to prevent premature CDK1 activation and mitotic entry until DNA is properly replicated or repaired. It is unclear how Chk1 activity is controlled in the unperturbed cell cycle. During DNA damage, Chk1 is activated by ataxia telangiectasia and Rad3 related (ATR)-mediated phosphorylation; however, it is not entirely clear how this phosphorylation results in Chk1 activation. Here we report an N-terminally truncated alternative splice variant of Chk1, Chk1-S. Importantly, we show that Chk1-S is an endogenous repressor and regulator of Chk1. In the unperturbed cell cycle, Chk1-S interacts with and antagonizes Chk1 to promote the S-to-G2/M phase transition. During DNA damage, Chk1 is phosphorylated, which disrupts the Chk1-Chk1-S interaction, resulting in free, active Chk1 to arrest the cell cycle and facilitate DNA repair. Higher levels of Chk1-S are expressed, along with Chk1, in fetal and cancer tissues than in normal tissues. However, forced overexpression of Chk1-S in cultured cells and tumor xenografts induces premature mitotic entry, mitotic catastrophe, and reduction of tumor growth. The identification of Chk1-S as a unique splice variant and key regulator of Chk1 provides insights into cell cycle regulation and DNA damage response.

Citing Articles

Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer.

Yip H, Shin S, Chee A, Ang C, Rossello F, Wong L NPJ Precis Oncol. 2024; 8(1):20.

PMID: 38273040 PMC: 10810864. DOI: 10.1038/s41698-024-00496-y.


3D spheroid culturing of Astyanax mexicanus liver-derived cell lines recapitulates distinct transcriptomic and metabolic states of in vivo tissue environment.

Biswas T, Rajendran N, Hassan H, Li H, Zhao C, Rohner N J Exp Zool B Mol Dev Evol. 2024; 342(3):301-312.

PMID: 38192038 PMC: 11060904. DOI: 10.1002/jez.b.23236.


Zinc finger protein 24-dependent transcription factor SOX9 up-regulation protects tubular epithelial cells during acute kidney injury.

Kim J, Silvaroli J, Vasquez Martinez G, Bisunke B, Luna Ramirez A, Jayne L Kidney Int. 2023; 103(6):1093-1104.

PMID: 36921719 PMC: 10200760. DOI: 10.1016/j.kint.2023.02.026.


RNA splicing dysregulation and the hallmarks of cancer.

Bradley R, Anczukow O Nat Rev Cancer. 2023; 23(3):135-155.

PMID: 36627445 PMC: 10132032. DOI: 10.1038/s41568-022-00541-7.


Construction of a Versatile, Programmable RNA-Binding Protein Using Designer PPR Proteins and Its Application for Splicing Control in Mammalian Cells.

Yagi Y, Teramoto T, Kaieda S, Imai T, Sasaki T, Yagi M Cells. 2022; 11(22).

PMID: 36428958 PMC: 9688318. DOI: 10.3390/cells11223529.


References
1.
Lam M, Liu Q, Elledge S, Rosen J . Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell. 2004; 6(1):45-59. DOI: 10.1016/j.ccr.2004.06.015. View

2.
Walworth N . Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol. 2000; 12(6):697-704. DOI: 10.1016/s0955-0674(00)00154-x. View

3.
Kastan M, Bartek J . Cell-cycle checkpoints and cancer. Nature. 2004; 432(7015):316-23. DOI: 10.1038/nature03097. View

4.
Ma C, Janetka J, Piwnica-Worms H . Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med. 2010; 17(2):88-96. PMC: 6905465. DOI: 10.1016/j.molmed.2010.10.009. View

5.
Kramer A, Lukas J, Bartek J . Checking out the centrosome. Cell Cycle. 2004; 3(11):1390-3. DOI: 10.4161/cc.3.11.1252. View